Diabetic population mortality and cardiovascular risk attributable to hypertension: A decade follow-up from the Tehran Lipid and Glucose Study

Blood Pressure

Volumn 22, Issue 5, 2013, Pages 317-324

  Bozorgmanesh, Mohammadreza ^a   Hadaegh, Farzad ^a   Mohebi, Reza ^a   Ghanbarian, Arash ^a   Eskandari, Fatemeh ^a   Azizi, Fereidoun ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardiovascular disease; Diabetes; Hypertension; Mortality; Population attributable hazard fraction

Indexed keywords

GLUCOSE; LIPID;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

ADULT; BLOOD PRESSURE DETERMINATION; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; IRAN; MALE; MIDDLE AGED; SMOKING; TREATMENT OUTCOME;

EID: 84884696208     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2013.769294     Document Type: Article

References (48)

1. Safran MA,Vinicor F. The war against diabetes. How will we know if we are winning? Diabetes Care. 1999;22:508-516
2. Fox CS, Coady S, Sorlie PD, D'Agostino RB, Sr., Pencina MJ, Vasan RS, et al. Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart Study. Circulation. 2007;115:1544-1550
3. Bozorgmanesh M, Hadaegh F, Sheikholeslami F, Azizi F. Cardiovascular risk and all cause mortality attributable to diabetes: Tehran Lipid and Glucose Study. J Endocrinol Invest. 2012;35:14-20
4. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: An update. Hypertension. 2001;37:1053-1059
5. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ. 1998; 316:823-828
6. Hypertension in Diabetes Study (HDS): II. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients: The Hypertension in Diabetes Study Group. J Hypertens. 1993;11:319-325
7. Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NRC. Cardiovascular outcomes in Framingham participants with diabetes. Hypertension. 2011;57:891-897
8. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials. 2009;10:5
9. Freedman DS, Kahn HS, Mei Z, Grummer-Strawn LM, Dietz WH, Srinivasan SR, et al. Relation of body mass index and waist-To-height ratio to cardiovascular disease risk factors in children and adolescents: The Bogalusa Heart Study. Am J Clin Nutr. 2007;86:33-40
10. Hadaegh F, Harati H, Ghanbarian A, Azizi F. Association of total cholesterol versus other serum lipid parameters with the short-Term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. Eur J Cardiovasc Prev Rehabil. 2006;13:571-577
11. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-Summary article: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation. 2003;107: 149-158
12. BraunwalDe, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-STsegment elevation myocardial infarction-2002: Summary article: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002;106:1893-1900
13. Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff DC, Jr., Havas S, et al. ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: A report of the American College of Cardiology Foundation/ American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention of cardiovascular disease): Developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: Endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. Circulation. 2009;120:1296-1336
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289:2560-2572
15. Chen YQ, Hu C, Wang Y. Attributable risk function in the proportional hazards model for censored time-To-event. Biostatistics. 2006;7:515
16. Samuelsen SO, Eide GE. Attributable fractions with survival data. Stat Med. 2008;27:1447-1467
17. Silverberg MJ, Smith MW, Chmiel JS, Detels R, Margolick JB, Rinaldo CR, et al. Fraction of cases of acquired immunodeficiency syndrome prevented by the interactions of identified restriction gene variants. Am J Epidemiol. 2004; 159:232-241
18. Laaksonen MA, Knekt P, Härkänen T, Virtala E, Oja H. Estimation of the population attributable fraction for mortality in a cohort study using a piecewise constant hazards model. Am J Epidemiol. 2010;171:837-847
19. Levin ML. The occurrence of lung cancer in man. Acta-Unio Internationalis Contra Cancrum. 1953;9:531-541
20. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. Circulation. 2007;115: 114-126
21. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: Meta-Analysis of randomised controlled trials. BMJ. 2011; 343:d4169
22. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. JAMA. 2002;287:2570-2581
23. Søren Christensen Kjærgaard H-HTH, Lars Fog, Inge Bülow, Per Dahl Christensen. In-hospital outcome for diabetic patients with acute myocardial infarction in the thrombolytic era. Scand Cardiovasc J. 1999;33:166-170
24. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al. Impact of diabetes on long-Term prognosis in patients with unstable angina and non-Q-Wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102:1014-1019
25. Zuanetti G, Latini R, Maggioni A, Santoro L, Franzosi M. Influence of diabetes on mortality in acute myocardial infarction: Data from the GISSI-2 study. J Am Coll Cardiol. 1993;22:1788-1794
26. Shindler DM, Palmeri ST, Antonelli TA, Sleeper LA, Boland J, Cocke TP, et al. Diabetes mellitus in cardiogenic shock complicating acute myocardial infarction: A report from the SHOCK Trial Registry. J Am Coll Cardiol. 2000;36(3-Suppl-A):1097-1103
27. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003;26:917-932
28. Narayan KMV, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290:1884-1890
29. American Diabetes Association. Standards of Medical Care in Diabetes-2013. Diabetes Care. 2013;36 Supplement 1:S11-S66
30. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, et al. Intensive glycaemic control for patients with type 2 diabetes: Systematic review with meta-Analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343:d6898
31. Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-Analysis of randomised controlled trials. The Lancet. 2009;373:1765-1772
32. Conget I, Giménez M. Glucose control and cardiovascular disease. Diabetes Care. 2009;32 Suppl 2:S334-S336
33. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO -HOPE substudy. The Lancet. 2000;355:253-259
34. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GEHM, Sandbæk A, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITIONEurope): A cluster-randomised trial. The Lancet. 2011; 378:156-167
35. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317:713-720
36. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med. 1999;340:677-684
37. Samadi S, Bozorgmanesh M, Khalili D, Momenan A, Sheikholeslami F, Azizi F, et al. Hypertriglyceridemic waist: The point of divergence for prediction of CVD vs. mortality: Tehran Lipid and Glucose Study. Int J Cardiol. 2011 Sep 15 [Epub ahead of print].
38. Hamid Zargar A, Iqbal Wani A, Rashid Masoodi S, Ahmad Laway B, Iftikhar Bashir M. Mortality in diabetes mellitus-Data from a developing region of the world. Diabetes Res Clin Pract. 1999;43:67-74
39. Wong JSK, Pearson DWM, Murchison LE, Williams MJ, Narayan V. Mortality in diabetes mellitus: Experience of a geographically defined population. Diabetic Med. 1991;8: 135-139
40. Mirmiran P, Ramezankhani A, Hekmatdoost A, Azizi F. Effect of nutrition intervention on non-communicable disease risk factors among Tehranian adults: Tehran Lipid and Glucose Study. Ann Nutr Metab. 2008;52:91-95
41. Harati H, Hadaegh F, Momenan AA, Ghanei L, Bozorgmanesh MR, Ghanbarian A, et al. Reduction in incidence of type 2 diabetes by lifestyle intervention in a middle eastern community. Am J Prev Med. 2010;38:628-636
42. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Statist Soc Ser B. 1995:289-300
43. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979:549-556
44. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Statist. 2001:1165-1188
45. Heller RF, Dobson AJ, Attia J, Page J. Impact numbers: Measures of risk factor impact on the whole population from case-control and cohort studies. J Epidemiol Community Health. 2002;56:606-610
46. Walter SD. Calculation of attributable risks from epidemiological data. Int J Epidemiol. 1978;7:175-182
47. Benichou J. A review of adjusteDestimators of attributable risk. Stat Methods Med Res. 2001;10:195-216
48. Rockhill B, Newman B, Weinberg C. Use and misuse of population attributable fractions. Am J Public Health. 1998;88: 15-19